Survey of Medical Liaison Practices 3: Assessing Practice Trends across the Pharmaceutical Industry

  • PDF / 12,402,324 Bytes
  • 15 Pages / 612 x 792 pts (letter) Page_size
  • 90 Downloads / 205 Views

DOWNLOAD

REPORT


Survey of Medical Liaison Practices 3: Assessing Practice Trends Across the Pharmaceutical Industry In an f l m t to assess m d d liaison tnnas

J. Lynn Bats, PbarmD Senior Regional Medical Liaison, Amgen, lnc Cbrirtopbrr I. Marronr, PbormD Outcomes Liaison, Eli Lilly and Company Craig Klingrr, RPb Senior Medical Liaison Consultant, Eli Lilly and Company

Kry Words Medical liaison; Pharmaceutical industry; Field-based; Employment; Survey; Benchmarking Corrrspondrncr Addrrrr J. Lynn Bass, PharmD. I2 I Five Oaks Circle, Beaufort, SC29902 (email: jbass@ amgen.com) . Data previously presented at the 43rdAnnual Drug Information Association Annual Meeting, Atlanta. Georgia, June 2007.

across thc phannnautid industy, two surveys of d d iiaison managas were prcM’ously administd and publiskcd. Tkc intent of these was to iduttib overall ap-

pnrachcs used by pkmmrPccutical companies in dcfiningand managing the mcdiocd h&hn de.We con&cted this third survey to fon meas identified by the initial survey participants as major challenges. In addition, we aimed to h d e n our survey to indude responses jkom both medid liaison managm and fidd-based medical liaisons. Ihc cuwent

INTRODUCTION Within the last decade, there has been a steady rise in the number of medical science liaison (MSL)groups within the pharmaceutical industry (1).With this evolution, new areas of focus are arising within the role. The traditional role of the medical liaison is to develop and maintain relationships with key opinion leaders within the health care community. A mutually beneficial relationship contributes to an environment of scientific exchange with the goal of improved outcomes for providers and patients. Activities of medical liaisons include dissemination of medical information upon request, exploration of mutual clinical and scientific interests with health care providers, and understanding the dynamics and unmet needs within the medical community. There exists a relative absence of in-depth published benchmarking data on medical liaison groups across the pharmaceutical industry. To fill this gap, two previous surveys were conducted by this group (2,3). The intent of the first survey was to initially identify the overall approaches used by pharmaceutical companies in defining and managing the medical liaison

survey focused on faur areas: the d c of medi d liaisosls in winpetitbe intelligence,

t r a d i t i d medical

liaison fidd d l potentially grow in the fibre.

role (2). The survey demonstrated that there are some similarities in medical liaison positions across the industry, such as reporting structure, job responsibilities, and medical liaison credentials. The second survey was a follow-up to explore two key areas identified in the initial survey (3). These areas of common challenges across the industry were training of new and experienced medical liaisons, and demonstrating the value of medical liaison organizations (3). This current survey was administered to explore evolving areas of focus of the medical liaison role, including compe